|Bid||132.55 x 300|
|Ask||134.85 x 300|
|Day's Range||132.85 - 135.16|
|52 Week Range||109.32 - 137.08|
|PE Ratio (TTM)||22.36|
|Dividend & Yield||3.36 (2.48%)|
|1y Target Est||N/A|
A lower-priced version of blockbuster Remicade hasn’t sold well; will an even cheaper drug upend the obscure pricing of the drug industry?
South Korea’s Samsung conglomerate, best known for its smartphones and televisions, will make available in the U.S. its lower-price copy of Johnson & Johnson’s blockbuster arthritis drug Remicade.
The Pennsauken, New Jersey-based company said it had profit of $1.34 per share. The drink and snack maker posted revenue of $295.4 million in the period. J&J Snack Foods shares have increased 3 percent ...